





TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER. School of Medicine Cancer Center

## **Cell Line Data Sheet for CHLA-10**

Disease: Phase of Therapy: Treatment: Disease Stage: Gender: Age at diagnosis: Race: Age at sample collection: Source of Culture: Primary Tumor Site: Date Established:	Primitive neuroectodermal tumor (PNET) Post-Chemotherapy (Progressive Disease) 4 cycles of cisplatin, doxorubicin, cyclophosphamide, etoposide Female 168 years N/A N/A N/A Solid tumor (thoracic lymph node) Thorax 1987
EWS/FLI1 Status: p53 functionality: Karyotype: Modal No:	FLI1 Non-Functional
R-IC50 (DIMSCAN*): *see reference 3	Vincristine (ng/ml)Melphalan ( $\mu$ g/ml)Etoposide (ng/ml)Rapamycin (ng/ml)0.39 ± 0.057.27 ± 1.200.12 ± 0.010.62 ± 0.08
Growth Conditions:	Please see Protocols section at <u>https://www.cccells.org/protocols.php</u> 5% CO <sub>2</sub> , 20% O <sub>2</sub> , 37.0°C
Media Formulation:	Please see Protocols section at <u>https://www.cccells.org/protocols.php</u> Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)
Doubling Time: Growth Properties:	32 hours Teardrop-shaped cells with processes, adherent, grow mostly in clumps
STR Profile:	May be obtained at https://strdb.cccells.org/
Notes:	The Childhood Cancer Repository has a matching direct-to-culture diagnosis cell line available from this same patient – CHLA-9

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.





л п


TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER School of Medicine Cancer Center

## **Cell Line Data Sheet for CHLA-10**

## References:

- Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at Other Tumor Suppressor Loci in Neuroblastoma. Cancer Res. 61, 679-686, 2001. PubMed ID: 11212268 <u>https://cancerres.aacrjournals.org/content/61/2/679.long</u>
- Batra S, Reynolds CP, Maurer BJ. Fenretinide cytotoxicity for Ewing's sarcoma (ES) and primitive neuroectodermal Tumor (PNET) cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Research 64: 5415-5424, 2004. PubMed ID: 15289350 <u>https://cancerres.aacrjournals.org/content/64/15/5415.long</u>
- Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. Pediatr Blood Cancer 56: 239-249, 2011. PubMed ID: 20922763 <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/</u>

SEE NCI Pediatric Preclinical Testing Program references.



TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER. School of Medicine TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER.